Market Place
Sourcing Support
Sumitomo brings together `Go-Getters` to talk overactive bladder
04 Dec 2024 //
FIERCE PHARMA
Joint Venture Established for Incubation of Drug Discovery Programs
08 Oct 2024 //
PR NEWSWIRE
Sumitomo Sets Out for Reconstruction, Further Cost Cuts in FY2024
02 May 2024 //
PHARMA JAPAN
Endometriosis Global Clinical Trials Review 2024
02 Apr 2024 //
BUSINESSWIRE
Otsuka and Sumitomo Revise License Agreement
15 Mar 2024 //
PRESS RELEASE
Sumitomo Pharma lays off 400 US staffers as sales slide
06 Mar 2024 //
FIERCE PHARMA
Sumitomo announces authorization in Canada of Orgovyx for prostate cancer
25 Oct 2023 //
INDIAN PHARMA POST
Sumitomo Pharma Announces Authorization in Canada of ORGOVYX
23 Oct 2023 //
PR NEWSWIRE
Sumitomo and Pfizer in Canada Receive Health Canada Approval for MYFEMBREE®
19 Oct 2023 //
PR NEWSWIRE
Gedeon Richter and Sumitomo Pharma Receive Positive CHMP Opinion for RYEQO
15 Sep 2023 //
PR NEWSWIRE
Salipro Biotech enters into research collaboration with Sumitomo Pharma
12 Sep 2023 //
GLOBENEWSWIRE
Sumitomo Announces Positive Results from Phase 3 Studies Evaluating Vibegron
11 Sep 2023 //
PR NEWSWIRE
Sumitomo, Otsuka’s Schizophrenia Candidate Fails Phase III Trials
01 Aug 2023 //
BIOSPACE
Sumitomo Launches as Combined Organization with Expanded Scale & Capabilities
10 Jul 2023 //
PR NEWSWIRE
Sumitomo will lay off 62 New York workers after consolidating seven subsidiaries
08 Jul 2023 //
ENDPTS
Sumitomo Presents Preliminary Data from Phase 1/2 Study Evaluating TP-3654
09 Jun 2023 //
PR NEWSWIRE
Sumitomo to make 200+ staff cuts in Massachusetts amid consolidation
02 May 2023 //
ENDPTS
Veneno, Novel DRP Drug Discovery Company, Joint Research Agreement with Sumitom
18 Apr 2023 //
PR NEWSWIRE
Sumitomo Pharma Oncology Receives Orphan Drug Designation for TP-1287
10 Apr 2023 //
PR NEWSWIRE
Sumitomo Pharma tidies up 7 units into 1 combined U.S. entity
03 Apr 2023 //
FIERCE BIOTECH
Kyorin and Sumitomo to introduce drug for overactive bladder in Taiwan
10 Mar 2023 //
BIOSPECTRUM ASIA
Sumitomo invests in Alpha Fusion for Targeted Alpha Therapy
08 Mar 2023 //
BUSINESSWIRE
GARDP and Sumitomo Pharma announce partnership in search for new antibiotics
24 Nov 2022 //
BIOSPECTRUMASIA
Big layoffs coming for Novartis, Sumitomo, Valneva
10 Nov 2022 //
FIERCEPHARMA
Myovant rejects Sumitomo`s buyout offer—at least for now
04 Oct 2022 //
FIERCEPHARMA
Myovant`s Board Confirms Sumitovant & Sumitomo to Acquire Remaining Shares
02 Oct 2022 //
GLOBENEWSWIRE
Sumitomo Pharma Oncology Receives ODD for DSP-0390 for Brain Cancer
18 Jul 2022 //
PRNEWSWIRE
Sumitomo Pharma Oncology Receives ODD for TP-3654 in Myelofibrosis
08 Jun 2022 //
PRNEWSWIRE
Myovant and Accord Healthcare enter licence agreement to commercialise Orgovyx
13 May 2022 //
EXPRESS PHARMA
Myovant Sciences and Accord Healthcare Enter into License Agreement for ORGOVYX
09 May 2022 //
GLOBENEWSWIRE
Jazz doubles down on sleep disorders, putting down $50M cash on Sumitomo drug
06 May 2022 //
ENDPTS
Myovant, Pfizer Provide Update on sNDA for MYFEMBREE in Endometriosis
06 May 2022 //
GLOBENEWSWIRE
Jazz and Sumitomo Announce Exclusive License Agreement for DSP-0187
04 May 2022 //
PRESS RELEASE
Sumitomo Presents New Data from Novel Cancer Therapeutics at AACR
08 Apr 2022 //
PRNEWSWIRE
Nabriva shares rise after Xenleta approval in Taiwan
08 Sep 2021 //
SEEKING ALPHA
Lefamulin Receives Approval in Taiwan for Community-Acquired Pneumonia
08 Sep 2021 //
GLOBENEWSWIRE
